Original articlesThoracic tumorsEditor's ChoiceCrizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
Thoracic tumors
Editor's Choice
Under a Creative Commons license
open access
Key words
crizotinib
non-small-cell lung cancer
ROS1
overall survival
Cited by (0)
Copyright © 2019 THE AUTHORS. Published by Elsevier Ltd.